Oncology News Articles

Goss PE et al. – Exemestane significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer. During a median follow-up period of 3 years, exemestane was associated with no serious toxic effects and only minimal changes in health-related quality of life.

• Randomized, placebo-controlled, double-blind trial of exemestane
• Study designed to detect 65% relative reduction in invasive breast cancer, eligible postmenopausal women 35 years of age or older had at least 1 of the following risk factors: 60 years of age or older; Gail 5-year risk score greater than 1.66% (chances in 100 of invasive breast cancer developing within 5 years); prior atypical ductal or lobular hyperplasia or lobular carcinoma in situ; or ductal carcinoma in situ with mastectomy
• Toxic effects and health-related and menopause-specific qualities of life measured

• 4560 women for whom median age was 62.5 years and median Gail risk score was 2.3% were randomly assigned to either exemestane or placebo
• At median follow-up of 35 months, 11 invasive breast cancers detected in ...read more

Read all Oncology News articles at MDLinx.com